Get started

Biotech

$BVNRY PTs 300-400 and higher Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
OTC:BVNRYLong
by BADQOMOCAWGOWLD
1
XBI outlook on future medicine We see it in our favorite sci fi movies: the cure for cancer, biotech armor, mind altering substances to enhance intelligence, so on so forth. Assuming this index is the representation of biotech importance, I'd like to hear ideas for how biotech would crash. Everything we've seen from the movies can be reasons for an increase in price.. but what would cause the destruction of biotech funding? Is it even possible? If we want to achieve space exploration.. how could biotech ever fail? Thanks.
AMEX:XBILong
by W40kProfit
SESEN Bio - A possible Jump & Run?The market is bleeding, but may be you know this quote: "Bull markets are born on pessimism, grow on skepticism, mature on optimism, and die on euphoria" - Sir John Templeton So the actual question is, where are we right now? I guess "Euphoria" is actually over and we are on our steady way down to realistic valuations. Let's talk facts: As of March 31, 2022, $SESN had $169.8 million in cash and cash equivalents, no outstanding debt and fewer than 0.2 million outstanding warrants. What is in their pipeline? They are currently developing Vicineum, a locally administered fusion protein, for the treatment of non-muscle invasive bladder cancer (NMIBC). What happened to the stock price? A few months ago the FDA had determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. The stock price dropped dramatically and now trades around 0.50$. What is BLA? BLA, Biologics License Application, is a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce (21 CFR 601.2). What opportunities lie ahead? Let me tell you, trading bio-tech stocks requires strong guts and control of emotions - I speak from experience. Currently the company is considering two things: 1. Reverse Split, so that they will remain listed on the NASDAQ 2. Selling the company to maximize shareholder value The development of Vicineum will continue and they seek another meeting with the FDA soon to discuss further steps for BLA approval with an additional Phase 3 testing. The 2nd option sounds like a good strategy, the balance sheet looks healthy, the product itself seems promising, so that I had to invest a little bit (10% of my account size). As soon as the company had communicated that they consider selling the company, the stock jumped a nice 30% - luckily I had bought it a few days earlier. Now we can see a little bit of pullback, which seems more like accumulation, rather than distribution. The volume on the declining candles is lower and the strong buy volume after the news actually speaks a different story. You can check my chart for levels (white are monthly and purple are the weekly levels of support and resistance). Let's see what will happen, but the most important thing is patience, as well as proper risk management. Stay healthy!
SLong
by RedFoxTrading
2
CRXT Clarus Therapeutics Bullish ReversalCRXT Clarus Therapeutics had 3 green days after its sell-off to all time low. This should signal a reversal pattern. Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO. The fist target is the $1.1 private placement offering price and then the $2.10 resistance. Few months ago they had another private placement at $4.96 per unit, so we can take that into consideration as well. Needham & Company LLC has a Price Target of $8 for CRXT (that is the ultimate goal). I think it can easily double from here. Looking forward to read your opinion about it.
CLong
by TopgOptions
$BTTXBetter Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
BLong
by BADQOMOCAWGOWLD
1
IBB Biotech reversal pattern after bounce from TL; low may be inIBB bounced from the green pandemic support zone last March but have came back down to retest this zone. IBB has found support exactly on my GANN FAN line for several times before it breaks down & retested the violet downtrend line & bounced, making a reversal with a long hammer candle. IBB may close today above my GANN FAN line support confirming reversal . Closing the next few days above 124 the pre-pandemic high would give added confidence to the bottom reversal pattern. Next resistances are 127 & 136 to make a higher high. Not trading advice
NASDAQ:IBBLong
by xtremerider8
$BCTX poised to bounce $BCTX - BriaCell is a cancer treatment biotech that recently dropped 40% AFTER receiving fast track designation for FDA approval. The drop was somewhat coincidental as it's month long bull run finished with a FinTwit pump and dump. BUT the retrace is in and it's approaching historical trend lines and levels of support and looks poised to bounce in the coming week. TD9 is flashing a buy signal, but I wouldn't be shocked if it begins to curl throughout the week. Looking to enter a long swing trade to ride it back to previous highs.
NASDAQ:BCTXLong
by runawaysun
1
$SRRA Long term PTs 79-145 and higher...Parabolic! (HCW)Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
SLong
by BADQOMOCAWGOWLD
$PFE Key Levels, Analysis, & Targets $PFE Key Levels, Analysis, & Targets Swing setup 1 at 47.59 1 at 45.65 2 at 41.06 4 at 38.36 8 at 34.40 (Then multiply by your multiplier (x5, x10, x100, x1000, etc to find your position size) Looking for 15%, up to 20% if all targets hit… --- I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading. IF you need anything analyzed Technically just comment with the Ticker and I’ll do it as soon as possible…
NYSE:PFEShort
by SPYder_QQQueen_Trading
NTLA Intellia Therapeutics Inc. BPC Chart Overview 03/28/22Intellia Therapeutics Inc. NASDAQ: NTLA Chart Overview 03/28/22 Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tracking support at $56 and a resistance line is at $90. The downward channel pullback may be forming a descending wedge, which could lead to a bullish breakout. Tracking RSI and MACD, the lowest lows on both charts are displaying a slight increase, running opposite to price, which lowest lows are continuing to decrease. The bullish divergence also indicates a possible breakout if met with an increase in volume. Good news could mean that the recent bottom is in, possible clinical holds, or other issues could test 2021 lows around $44. We will be looking for a breakout over $90 into a new bullish pattern. Intellia will be commencing Part 2 of its NTLA-2001 and is set to read out from its Phase 1/2 NTLA-2002 hereditary angioedema (HAE) trial this year. A recent loss in a CRISPR patent ruling increases uncertainty in the stock. Catalysts can have a profound effect on stock price and incorporating BioPharmCatalyst into your due diligence can ensure that you are prepared. Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
NASDAQ:NTLA
by BioPharmCatalyst
BCTX BriaCell Therapeutics Corp: BPC Chart Overview 03/28/22BriaCell Therapeutics Corp. NASDAQ: BCTX Chart Overview 03/28/22 BriaCell broke out of a 3-month downward channel into an upward channel. We are tracking support lines at $4.20, $5, and $5.89, and resistance lines at $9.60 and $10.47. Friday and today shares are trading overextended and coming up to resistance both in terms of channel lines, candlesticks, resistance price at $6.90. Shares are currently trading above the 1st resistance at $9.60, and we will be watching changes in volume to confirm the breakout. Through utilizing the Stochlistics chart, it appears that the price is overbought and a possible indicator of a return to the pattern. If the channel holds then we will look to retest the $6.90 resistance to see if it breaks out and moves higher into new recent highs. Track 1000+ catalysts and access over 800+ companies’ fundamentals, earnings and analyst ratings by becoming a BPC Premium Subscriber. Sign up for your FREE trial at www.biopharmcatalyst.com Get a daily breakdown of biotech investor news straight to your inbox with our pre and post market newsletters sign up here www.biopharmcatalyst.com
NASDAQ:BCTX
by BioPharmCatalyst
Elevation Oncologys personalised treatment plans for cancer ⚕️I find that the cash ($146M) vs valuation (55M) is rocket fuel for “the herd”. Also presenting itself as an “undiscovered gem” may contribute to a good ol’ pop. They have good social media skills and their website is gorgeous. Being that this will be about as much DD as the masses ever do it can and most times is quite important for fueling said pop. RSI in the low lows lends a little more to the “undiscovered gem” ideology even though I loath technical analysis many do not. News about their phase II study (which they seem to be taking very seriously) should come to light within the following months and as any biotech investor knows: news + biotech = insane short term gains. Check out my ideas on Utradea
NASDAQ:ELEVLong
by Magnus_Chimpski